Duloxetine Hcl Capsule, Delayed Release
Product Images NDC 80425-0146

13 FDA label images from Advanced Rx Pharmacy Of Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Image)

Structure (Image)
Chemical structure of Duloxetine HCL, showing the molecular arrangement including the thiophene ring, naphthalene group, and amine with HCl component, as depicted in the image for Duloxetine HCL DR.*
FDA Label Image

Figure 1 (Image 2)

Figure 1 (Image 2)
A line graph showing the proportion of patients with relapse over time from randomization to relapse in days. Two treatments are compared: Placebo (dashed line) and Duloxetine (solid line). The y-axis represents the proportion of patients with relapse from 0.0 to 1.0, and the x-axis represents time in days up to 250. The graph indicates that the proportion of patients with relapse is higher for Placebo compared to Duloxetine over the observed period.*
FDA Label Image

Figure 2 (Image3)

Figure 2 (Image3)
A Kaplan-Meier curve graph showing the proportion of patients with relapse over time from randomization (days) comparing two treatments: placebo and duloxetine. The x-axis measures time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The duloxetine curve shows a lower relapse proportion compared to placebo throughout the study period.*
FDA Label Image

Figure 3 (Image4)

Figure 3 (Image4)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares the efficacy of these doses and placebo in pain improvement across a range from 0 to 100 percent.*
FDA Label Image

Figure 4 (Image 6)

Figure 4 (Image 6)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. The Duloxetine groups show higher improvement percentages compared to placebo across the range.*
FDA Label Image

Figure 5 (Image5)

Figure 5 (Image5)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient improvement rates decreasing as percent pain improvement thresholds increase.*
FDA Label Image

Figure 6 (Image7)

Figure 6 (Image7)
A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing trends of patient improvement across different pain reduction thresholds.*
FDA Label Image

Figure 8 (Image 8)

Figure 8 (Image 8)
A line chart comparing the percentage of patients improved by placebo versus Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines represent placebo and Duloxetine groups, displaying patient improvement across pain reduction thresholds.*
FDA Label Image

Figure 9 (Image9)

Figure 9 (Image9)
A line graph comparing the percentage of patients improved between placebo and Duloxetine 60 mg once daily based on percent improvement in pain from baseline (BOCF). The x-axis shows percent improvement categories from >0 to 100, and the y-axis displays the percentage of patients improved from 0 to 100%. Two lines represent placebo and Duloxetine groups, showing trends in patient improvement.*
FDA Label Image

Figure 10 (Image 10)

Figure 10 (Image 10)
A line chart comparing the percentage of patients improved based on percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily groups. The x-axis represents percent improvement from 0 to 100, while the y-axis shows the percentage of patients improved from 0% to 100%. Two descending trend lines are shown, with Duloxetine consistently having a higher percentage of patients improved compared to placebo at various pain improvement thresholds.*
FDA Label Image

Label 1 (Label 1)

Label 1 (Label 1)
Duloxetine HCL DR 30 mg delayed-release capsules packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label indicates a package count of 30 capsules and includes storage instructions (20°-25°C), lot number 30DUL30225, and expiration date 2/28/2025. It also compares this product to Cymbalta and shows the NDC 80425-0146-01. Manufacturer listed as Ajanta Pharma L.*
FDA Label Image

Label 2 (Label 2)

Label 2 (Label 2)
Duloxetine HCL 30 mg delayed-release capsule label. The label includes dosage strength, product type, packaging information by AdvancedRx Pharmacy of Tennessee, and directions to store at 20-25°C (68-77°F). It contains a caution for patients to read the Medication Guide and a comparison mention to Cymbalta with a corresponding NDC number. Manufacturer Ajanta Pharma L is noted on the label along with lot number and expiry date 6/30/2025.*
FDA Label Image

Label 3 (Duloxetine HCl Dr 80425 0146 03)

Label 3 (Duloxetine HCl Dr 80425 0146 03)
Duloxetine HCL DR 30 mg delayed-release capsule label showing packaging details. The label includes the product name, strength, dosage form, NDC number (80425-0146), manufacturer Advanced Rx Pharmacy of Tennessee, LLC, and instructions to store the product at 20°-25°C. The label also compares this product to Cymbalta and displays lot number and expiration date 6/30/2025.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.